Anxiety · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
1 finding from 1 review
no estimate extracted
180 participants
Very low
Depression · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
1 finding from 1 review
no estimate extracted
1412 participants
Very low
Time to detection of recurrence · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
1 finding from 1 review
no estimate extracted
1691 participants
Very low
Health‐related quality of life, (at 12 months' · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
Non‐specialist‐led showed no clear difference in health‐related quality of life, (at 12 months' compared with specialist‐led follow‐up after primary cancer treatment (low certainty).
1 finding from 1 review
MD 1.06
605 participants
Low
Anxiety · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
Non‐specialist‐led showed no clear difference in anxiety (at 12 months' compared with specialist‐led follow‐up after primary cancer treatment (moderate certainty).
1 finding from 1 review
MD 0.03
1266 participants
Moderate
Depressive symptoms · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
Non‐specialist‐led showed no clear difference in depression (at 12 months) HADS‐Depression subscale (higher scores… compared with specialist‐led follow‐up after primary cancer treatment (high certainty).
1 finding from 1 review
MD 0.03
1266 participants
High
Costs · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
1 finding from 1 review
no estimate extracted
1756 participants
Very low
Overall survival · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
Less intensive showed no clear difference in overall survival compared with more intensive follow‐up after primary cancer treatment (low certainty).
1 finding from 1 review
HR 1.05 [0.96, 1.14]
10726 participants
Low
Time to detection of recurrence · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
Less intensive probably leads to lower time to detection of recurrence compared with more intensive follow‐up after primary cancer treatment (moderate certainty).
1 finding from 1 review
HR 0.85 [0.79, 0.92]
11276 participants
Moderate
Health‐related quality of life · adult cancer survivors from the following cancer sites: breast, colorectal, head‐and‐neck, Hodgkin lymphoma, melanoma, non‐small cell lung…
1 finding from 1 review
no estimate extracted
2742 participants
Very low
All‐cause mortality during hospital stay · people with critical limb ischaemia
1 finding from 1 review
Rate of amputation · people with critical limb ischaemia
It is very uncertain whether high cell dose changes amputation rate Assessed during in‐patient stay (Losordo 2012) compared with low cell dose (very low certainty).
1 finding from 1 review
Ulcer healing · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rest‐pain relief · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · patients with acute asthma
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with artificial saliva; GRADE not reported.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Chinese medicine led to higher salivary flow rate (stimulated) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).
1 finding from 1 review